Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Design Therapeutics, Inc. (DSGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.73+0.35 (+2.43%)
At close: 01:00PM EST
14.73 -0.14 (-0.94%)
After hours: 01:01PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.38
Open14.40
Bid12.67 x 800
Ask14.87 x 1300
Day's Range14.40 - 15.02
52 Week Range9.61 - 26.30
Volume71,653
Avg. Volume352,263
Market Cap819.909M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.99
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.80
  • GlobeNewswire

    Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

    Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multiple-Ascending Dose Phase 1 Trial of DT-216; Trial Completion Anticipated in Mid-2023 Strong Financial Position with $344.2 Million in Cash and Securities to Support Multi-Year Operating Runway and Further Advancement of GeneTAC™ Platform CARLSBAD, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-s

  • GlobeNewswire

    Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

    Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022CARLSBAD, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-216, as a potential treatment for Friedreich ataxia (FA) will be presented during an oral sessio

  • GlobeNewswire

    Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

    CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC. A live webcast wil

Advertisement
Advertisement